Name: Latest research reports of Piramal Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635 | ISIN: INE0DK501011 | Industry: Pharmaceuticals
| Expensive Performer

171.2200 -1.63 (-0.94%)

NSE Dec 30, 2025 12:39 PM

Near 52W Low of ₹165.12

Volume: 746.4K

Piramal Pharma Ltd.

25 Sep 2024

171.22

-0.94%

Geared to drive robust operating leverage across segments

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

PIRPHARM is well-positioned to offer differentiated services at the product development and commercial manufacturing stage in the CDMO segment.

Piramal Pharma Ltd. has an average target of 262.67 from 3 brokers.